|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, Li
Y, Xu C, Ouyang G and Duan S: The diagnostic value of DNA
methylation in leukemia: A systematic review and meta-analysis.
PLoS One. 9:e968222014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weng HH, Tsai SS, Chen CC, Chiu HF, Wu TN
and Yang CY: Childhood leukemia development and correlation with
traffic air pollution in Taiwan using nitrogen dioxide as an air
pollutant marker. J Toxicol Environ Health A. 71:434–438. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo J, Cahill MR, McKenna SL and
O'Driscoll CM: Biomimetic nanoparticles for siRNA delivery in the
treatment of leukaemia. Biotechnol Adv. 32:1396–1409. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsai TC, Huang HP, Chang KT, Wang CJ and
Chang YC: Anthocyanins from roselle extract arrest cell cycle G2/M
phase transition via ATM/Chk pathway in p53-deficient leukemia
HL-60 cells. Environ Toxicol. 32:1290–1304. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lassalle P, Molet S, Janin A, Heyden JV,
Tavernier J, Fiers W, Devos R and Tonnel AB: ESM-1 is a novel human
endothelial cell-specific molecule expressed in lung and regulated
by cytokines. J Biol Chem. 271:20458–20464. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Balta S, Mikhailidis DP, Demirkol S,
Ozturk C, Kurtoglu E, Demir M, Celik T, Turker T and Iyisoy A:
Endocan-A novel inflammatory indicator in newly diagnosed patients
with hypertension: A pilot study. Angiology. 65:773–777. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toshikuni N, Ozaki K, George J and
Tsutsumi M: Serum endocan as a survival predictor for patients with
liver cirrhosis. Can J Gastroenterol Hepatol. 29:427–430. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balta I, Balta S, Koryurek OM, Demirkol S,
Mikhailidis DP, Celik T, Cakar M, Kucuk U, Eksioglu M and Kurt YG:
Serum endocan levels as a marker of disease activity in patients
with Behcet disease. J Am Acad Dermatol. 70:291–296. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mihajlovic DM, Lendak DF, Brkic SV,
Draskovic BG, Mitic GP, Novakov Mikic AS and Cebovic TN: Endocan is
useful biomarker of survival and severity in sepsis. Microvasc Res.
93:92–97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grigoriu BD, Depontieu F, Scherpereel A,
Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB and
Lassalle P: Endocan expression and relationship with survival in
human non-small cell lung cancer. Clin Cancer Res. 12:4575–4582.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maurage CA, Adam E, Mineo JF, Sarrazin S,
Debunne M, Siminski RM, Baroncini M, Lassalle P, Blond S and
Delehedde M: Endocan expression and localization in human
glioblastomas. J Neuropathol Exp Neurol. 68:633–641. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ozaki K, Toshikuni N, George J, Minato T,
Matsue Y, Arisawa T and Tsutsumi M: Serum endocan as a novel
prognostic biomarker in patients with hepatocellular carcinoma. J
Cancer. 5:221–230. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scherpereel A, Gentina T, Grigoriu B,
Senechal S, Janin A, Tsicopoulos A, Plenat F, Bechard D, Tonnel AB
and Lassalle P: Overexpression of endocan induces tumor formation.
Cancer Res. 63:6084–6089. 2003.PubMed/NCBI
|
|
15
|
Yang J, Sheng S, Yang Q, Li L, Qin S, Yu S
and Zhang X: Endocan silencing induces programmed cell death in
hepatocarcinoma. Oncol Lett. 14:5333–5339. 2017.PubMed/NCBI
|
|
16
|
Xu Z, Zhang S, Zhou Q, Wang Y and Xia R:
Endocan, a potential prognostic and diagnostic biomarker of acute
leukemia. Mol Cell Biochem. 395:117–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hatfield KJ, Lassalle P, Leiva RA, Lindas
R, Wendelboe O and Bruserud O: Serum levels of endothelium-derived
endocan are increased in patients with untreated acute myeloid
leukemia. Hematology. 16:351–356. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Zhou Q, Yu Z, Wu X, Chen X, Li J,
Li C, Yan M, Zhu Z, Liu B and Su L: Cancer-associated
fibroblast-derived Lumican promotes gastric cancer progression via
the integrin beta1-FAK signaling pathway. Int J Cancer.
141:998–1010. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo L, Ou S, Ma X, Zhang S and Lai Y:
MACC1 silencing inhibits cell proliferation and induces cell
apoptosis of lung adenocarcinoma cells through the beta-catenin
pathway. Neoplasma. 65:552–560. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu X, Song S, Wang Q, Yuan T and He J: A
mutation in beta-amyloid precursor protein renders SHSY5Y cells
vulnerable to isoflurane toxicity: The role of inositol 1,4,5
trisphosphate receptors. Mol Med Rep. 14:5435–5442. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qin M, Luo Y, Lu S, Sun J, Yang K, Sun G
and Sun X: Ginsenoside F1 ameliorates endothelial cell inflammatory
injury and prevents atherosclerosis in mice through A20-mediated
suppression of NF-κB signaling. Front Pharmacol. 8:9532017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rebollo J, Geliebter J and Reyes N: ESM-1
siRNA knockdown decreased migration and expression of CXCL3 in
prostate cancer cells. Int J Biomed Sci. 13:35–42. 2017.PubMed/NCBI
|
|
24
|
Bender O, Gunduz M, Cigdem S, Hatipoglu
OF, Acar M, Kaya M, Grenman R, Gunduz E and Ugur KS: Functional
analysis of ESM1 by siRNA knockdown in primary and metastatic head
and neck cancer cells. J Oral Pathol Med. 47:40–47. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao W, Sun M, Li S, Wang Y and Liu J:
Biological and clinical implications of endocan in gastric cancer.
Tumour Biol. 35:10043–10049. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Furuta C, Li C, Taneda S, Suzuki AK,
Kamata K, Watanabe G and Taya K: Immunohistological study for
estrogenic activities of nitrophenols in diesel exhaust particles.
Endocrine. 27:33–36. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ye D, Luo H, Lai Z, Zou L, Zhu L, Mao J,
Jacob T, Ye W, Wang L and Chen L: ClC-3 chloride channel proteins
regulate the cell cycle by Up-regulating cyclin D1-CDK4/6 through
suppressing p21/p27 expression in nasopharyngeal carcinoma cells.
Sci Rep. 6:302762016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hata AN, Engelman JA and Faber AC: The
BCL2 family: Key mediators of the apoptotic response to targeted
anticancer therapeutics. Cancer Discov. 5:475–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qin J, Xie LP, Zheng XY, Wang YB, Bai Y,
Shen HF, Li LC and Dahiya R: A component of green tea,
(−)-epigallocatechin-3-gallate, promotes apoptosis in T24 human
bladder cancer cells via modulation of the PI3K/Akt pathway and
Bcl-2 family proteins. Biochem Biophys Res Commun. 354:852–857.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dolcet X, Llobet D, Pallares J and
Matias-Guiu X: NF-κB in development and progression of human
cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pacifico F and Leonardi A: Role of
NF-kappaB in thyroid cancer. Mol Cell Endocrinol. 321:29–35. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang W, Nag SA and Zhang R: Targeting the
NFkappaB signaling pathways for breast cancer prevention and
therapy. Curr Med Chem. 22:264–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Madonna G, Ullman CD, Gentilcore G,
Palmieri G and Ascierto PA: NF-kappaB as potential target in the
treatment of melanoma. J Transl Med. 10:532012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lopez-Guerra M and Colomer D: NF-kappaB as
a therapeutic target in chronic lymphocytic leukemia. Expert Opin
Ther Targets. 14:275–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cilloni D, Martinelli G, Messa F,
Baccarani M and Saglio G: Nuclear factor kB as a target for new
drug development in myeloid malignancies. Haematologica.
92:1224–1229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kang YH, Ji NY, Han SR, Lee CI, Kim JW,
Yeom YI, Kim YH, Chun HK, Kim JW, Chung JW, et al: ESM-1 regulates
cell growth and metastatic process through activation of NF-kappaB
in colorectal cancer. Cell Signal. 24:1940–1949. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Baldwin AS: Regulation of cell death and
autophagy by IKK and NF-kappaB: Critical mechanisms in immune
function and cancer. Immunol Rev. 246:327–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Auberger P and Puissant A: Autophagy, a
key mechanism of oncogenesis and resistance in leukemia. Blood.
129:547–552. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang XY, Zhang XH, Peng L, Liu Z, Yang YX,
He ZX, Dang HW and Zhou SF: Bardoxolone methyl (CDDO-Me or RTA402)
induces cell cycle arrest, apoptosis and autophagy via
PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.
Am J Transl Res. 9:4652–4672. 2017.PubMed/NCBI
|
|
42
|
Sumei Z, Shaolong C, Xiang W, Yinliang Q,
Qing Z and Yuan W: Endocan reduces the malign grade of gastric
cancer cells by regulating associated protein expression. Tumour
Biol. 37:14915–14921. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cai L, Leng ZG, Guo YH, Lin SJ, Wu ZR, Su
ZP, Lu JL, Wei LF, Zhuge QC and Jin Kand Wu ZB: Dopamine agonist
resistance-related endocan promotes angiogenesis and cells
viability of prolactinomas. Endocrine. 52:641–651. 2016. View Article : Google Scholar : PubMed/NCBI
|
